Bengaluru-based online pharmacy startup PlatinumRx is negotiating a $32 million funding round led by the Belgian investment firm Sofina Ventures. The deal is expected to value the company between $150 million and $200 million.
Key Takeaways
- Proposed investment: PlatinumRx is seeking $32 million in new capital to scale its operations.
- Valuation shift: The deal values the startup at up to $200 million, a significant increase from its previous funding rounds.
- Business model: Founded in 2023, the platform focuses on providing affordable, substitute medications with identical compositions to prescribed drugs.
- Investor background: Previous backers include Stellaris Venture Partners and India Quotient, which led the startup’s $6 million Series A round last year.
- Market context: The move comes as investors continue to prioritize specialized healthcare platforms despite competition from quick-commerce medicine delivery services.
Expansion and Strategy
PlatinumRx, established by Ashutosh Pandey and Piyush Kumar, specializes in connecting consumers with cost-effective alternatives to branded pharmaceuticals. By sourcing medicines directly from manufacturers, the company aims to bridge the price gap for patients requiring chronic or recurring treatments. The startup reports that it has served over one million customers since its inception.
Previous capital infusions have supported the company’s infrastructure development, including the expansion of fulfillment centers and investments in supply chain technology. If finalized, this latest round will provide additional liquidity to further these efforts, allowing the company to strengthen its position in the competitive Indian pharmacy market.
Negotiations remain ongoing, and final terms regarding investor participation and valuation are subject to change. Representatives from both PlatinumRx and Sofina Ventures did not respond to requests for comment regarding the potential transaction.